Xyrem API Insight Report, 2018 - ResearchAndMarkets.com

August 24, 2018

DUBLIN--(BUSINESS WIRE)--Aug 24, 2018--The “Xyrem - API Insight, 2018” report has been added to ResearchAndMarkets.com’s offering.

Xyrem - API Insight, 2018 report provides product and API manufacturers’ details across US, Europe, China and India for Xyrem.

It includes Xyrem overview, mechanism, regulatory milestones, deals & partnerships, clinical trials and other development activities. It further provides Xyrem’s patents information (US & EU). It also features the historical and forecasted sales of Xyrem till 2022. The report also highlights Xyrem’s market competition and emerging therapies which are in the same space as Xyrem.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Key Topics Covered:

Xyrem - Overview Route of Synthesis Mechanism of Action Pharmacodynamics Pharmacokinetics Safety and Efficacy of Xyrem Xyrem: Patient Perception Adverse Reactions Deals and Partnerships Regulatory Milestones Product Description Product Details United States Europe Xyrem Global Sales Assessment Historical Global Sales Forecasted Global Sales Global API Manufacturers United States India Patent Details Market Competitors Competitive Landscape (Emerging Therapies) NLS-0: NLS Pharma Product Description Research and development Product Development Activities Appendix

For more information about this report visit https://www.researchandmarkets.com/research/5zrt49/xyrem_api_insight?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180824005280/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs,Software Design and Development



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/24/2018 11:18 AM/DISC: 08/24/2018 11:18 AM


Update hourly